IRMD
IRadimed Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth -12.5% ·
share flow +3.1% ·
net new positions -14.3%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 82 | -3 | 5.33M | $509.49M | +6 | −9 |
| Q1 2026 | 88 | +3 | 5.07M | $488.33M | +6 | −3 |
| Q4 2025 | 85 | 0 | 4.93M | $479.86M | +1 | −1 |
| Q3 2025 | 16 | +1 | 3.09M | $220.20M | +1 | n/a |
| Q2 2025 | 12 | +2 | 2.63M | $157.45M | +2 | n/a |
| Q1 2025 | 7 | -1 | 1.04M | $54.42M | n/a | −1 |
| Q4 2024 | 8 | +1 | 1.01M | $55.33M | +1 | n/a |
| Q3 2024 | 6 | -3 | 875.49K | $44.03M | n/a | −3 |
| Q2 2024 | 9 | n/a | 935.05K | $41.09M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 501.71K | -2.2% | $26.33M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 245.39K | +10.2% | $12.88M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 175.68K | +0.7% | $9.22M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Millennium Management ✦ | 70.15K | +59.2% | $3.68M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 19.01K | +2.8% | $997,487 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 15.83K | +7.5% | $830,709 | 0.0% | ▲ Add | 4 | SEC ↗ ×4 |
| 7 | D. E. Shaw & Co. ✦ | 9.15K | -30.4% | $480,297 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $291,720 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 225 holders, 7.61M shares, $667.38M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 1.01K sh · $87,650
Director · 405 sh · $34,972
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology